er-086526 has been researched along with Uterine-Neoplasms* in 2 studies
2 other study(ies) available for er-086526 and Uterine-Neoplasms
Article | Year |
---|---|
Tumour lysis syndrome following eribulin for metastatic uterine leiomyosarcoma.
A middle-aged woman with a history of leiomyosarcoma of the uterus treated with surgery and adjuvant chemotherapy suffered a bulky metastatic recurrence 1 year later. She elected treatment with palliative eribulin, presenting with acute renal failure and electrolyte abnormalities consistent with tumour lysis syndrome on cycle 1 day 8. Despite aggressive supportive care and treatment including intravenous hydration, bicarbonate and rasburicase, she continued to decline, ultimately foregoing haemodialysis in favour of palliative care and passed away in the hospital. Topics: Acute Kidney Injury; Antimitotic Agents; Fatal Outcome; Female; Furans; Humans; Ketones; Leiomyosarcoma; Liver Neoplasms; Middle Aged; Tumor Lysis Syndrome; Uterine Neoplasms | 2018 |
The treatment of uterine sarcomas.
Uterine sarcomas are rare and comprise only 3% of all uterine cancers. Within the group of adult soft tissue sarcomas, they account for ∼7% of new cases. They consist of several distinct histological subtypes like leiomyosarcoma, endometrial stromal tumors, undifferentiated sarcomas, pure heterologous sarcomas, and mixed epithelial and mesenchymal tumors. Standard treatment in localized disease is abdominal hysterectomy. Bilateral salpingo-oophorectomy and lymphadenectomy have no proven value in leiomyosarcomas and high-grade undifferentiated sarcomas. However, in endometrial stromal tumors, given the hormonal reponsiveness of most tumors, salpingo-oophorectomy is generally recommended. Carcinosarcomas are treated according to current recommendations for epithelial uterine cancers. In leiomyosarcomas, postoperative radiation does not improve both relapse-free and overall survival. adjuvant chemotherapy seems to improve survival in the context of uncontrolled phase II trials. However, it is currently not considered standard of care in the absence of data from randomized trials. In contrast, adjuvant chemotherapy does improve overall survival in carcinosarcomas and is therefore considered standard of care. Systemic therapy for advanced uterine leiomyosarcomas, undifferentiated uterine sarcomas, and heterologous sarcomas is generally following the recommendations for adult soft tissue sarcomas. Endometrial stromal sarcomas are usually hormonal receptor positive, which allows endocrine therapy in most cases. Topics: Chemotherapy, Adjuvant; Clinical Trials as Topic; Endometrial Stromal Tumors; Female; Furans; Humans; Ketones; Leiomyosarcoma; Neoplasm Staging; Sarcoma; Uterine Neoplasms | 2012 |